semaglutide bmi 27 Wegovy® – A New Treatment for Obesity Semaglutide 2.4 mg Clinical Outcomes

While we partner with FDA-registered and inspected pharmacies for the shipping of all weight loss medications, including compounded ones, we must clarify that compounded medications are not FDA-approved

Makhmutova et al

The SURPASS clinical trial program demonstrated that tirzepatide at its highest dose (15 mg weekly) produced average weight loss of 20-25% of body weight, significantly exceeding the results seen with GLP-1 only agonists

BPC-157 is not approved by Health Canada or the FDA for human or veterinary use and is not intended for human consumption

At Stonebridge Medical, were committed to personalized care and science-backed solutions

Endocrinology, Diabetes & Metabolism , 2 (3), e00068